Skip to main content
Dryad

Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients

Data files

Apr 21, 2025 version files 38.96 MB

Click names to download individual files

Abstract

Five patient-derived organotypic cultures from patients with treatment-naïve primary ER+/PR+/HER2- tumors while one came from a patient with neoadjuvant therapy for locally metastatic ERlow/PR-/HER2- tumor. They all exhibited tissue outgrowth in one month with some CA OTC harboring isolatable organoids and fibroblasts. We interrogated reprogrammed metabolism in CA versus paired NC OTC with dual 2H7-glucose/13C5,15N2-Gln tracers coupled with Stable Isotope-Resolved Metabolomic analysis. The data are provided as Excel spreadsheets for each patient. The entries comprise reduced data from FT-MS analyses in terms of identified compounds, their ion intensities for each isotopologue, injection volumes and derived normalized concentrations. These data can therefore be reanalyzed as desired.